## Top 200 Pharmaceutical Products by Retail Sales in 2015

Compiled and Produced by the Njardarson Group (The University of Arizona): David T. Smith, Brandon R. Smith, Haziq Qureshi, Jón T. Njarðarson

1 Humira ( Adalimumab )	2 Harvoni ( Ledipasvir and Sofosbuvir )	3 Enbrel (Etanercept)	4 Lantus ( Insulin Glargine )	5 Avastin ( Bevacizumab )	6 Herceptin ( Trastuzumab )	7 Remicade ( Infliximab )	8 Prevnar family (Pneumococcal 7-Valent Conjugate)	9 Revlimid ( Lenalidomide )	10 MabThera/Rituxan ( Rituximab )	11 Sovaldi (Sofosbuvir)	12 Seretide/Advair ( Salmeterol )	13 Crestor ( Rosuvastatin Calcium )	14 Total Lyrica ( Pregabalin )	15 Neulasta ( Pegfilgrastim )	16 Gleevec/Glivec	17 Copaxone (Glatiramer)	18 Januvia (Sitagliptin)	19 Tecfidera ( Dimethyl Fumarate )	20 Truvada (Emtricitabine, and Tenofovir Disoproxil Fumarate)
	HO F			(Sevasize Mas)	(Hasiozanias)			$NH_2$ $O$ $NH$ $O$		O H O O O O O O O O O O O O O O O O O O	HN O	OH OH OH OH OH	OH			$O = \begin{array}{c c} OH & OH & HO \\ \hline -NH_2 & $	F NH <sub>2</sub> O N N N N N N N N N N N N N N N N N N		H <sub>2</sub> N F
abbyie	GILEAD	AMGEN	SANOFI	Roche			Dizor	Celgene	Rocha	HOTIF	OH OH	A	H <sub>2</sub> N Ö	AMGEN	N N N N N N N N N N N N N N N N N N N	H <sub>2</sub> N O OH OH OH OH	F CF3  MERCK	Diagon	GILEAD
\$14,012 Million IMMUNOLOGY  21 Symbicort (Budesonide and Formoterol)	\$13,864 Million INFECTIOUS DISEASES  22 Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumaro	\$8,697 Million IMMUNOLOGY  23 NovoRapid/NovoLog (Insulin)	\$7,029 Million DIABETES  24 Abilify ( Aripiprazole )	\$6,751 Million ONCOLOGY  25 Humalog ( Insulin lispro )	\$6,603 Million ONCOLOGY  26 Gilenya (Fingolimod)	\$6,561 Million IMMUNOLOGY  27 Levemir (Insulin)	\$6,245 Million ANTI-BACTERIAL  28 Victoza ( Liraglutide )	\$5,801 Million BLOOD RELATED DISORDERS  29 Avonex (Interferon beta-1a)	\$5,696 Million ONCOLOGY  30 Soliris (Eculizumab)	\$5,276 Million INFECTIOUS DISEASES  31 Zetia (Ezetimibe)	\$5,227 Million RESPIRATORY DISORDERS  32 Nexium (Esomeprazole Magnesium)	AstraZeneca \$5,017 Million CARDIOVASCULAR  33 Alimta ( Pemetrexed )	\$4,839 Million  NEUROSCIENCE AND MENTAL HEALTH  34 Xarelto  ( Rivaroxaban )	\$4,715 Million BLOOD RELATED DISORDERS  35 Stelara ( Ustekinumab )	\$4,658 Million ONCOLOGY  36 Cialis ( Tadalafil )	\$4,023 Million NEUROSCIENCE AND MENTAL HEALTH   37 Zytiga ( Abiraterone Acetate )	\$3,863 Million DIABETES  38 Janumet ( Metformin and Sitagliptin )	\$3,638 Million NEUROSCIENCE AND MENTAL HEALTH  39 Plavix ( Clopidogrel Bisulfate )	\$3,459 Million INFECTIOUS DISEASES  40 Lucentis ( Ranibizumab )
OH NH OH OH	L'N OP OF	HO OH OH	( ) III pipi dzole )		ОН	HO OH OH	His Ala Glu Gly Thr Phe Thr Ser Ser Val Asp	( IIII of	(Edizorias)	O OH	N S N	OH OH OH	CI	Continuity	(Todalam)	N N	F NH <sub>2</sub> O N N	çı o	(Kariibizarrida)
HO HO H	N N N N N N N N N N N N N N N N N N N	HO OH OH	O NHO		NH <sub>2</sub> OH	OH OH OH	Gin Ala Ala Lys Giu Phe lle  Ala  Gly Arg Gly Arg Val Leu Trp  OH			F OH	O H	H <sub>2</sub> N N H	O NH		N H N H	HO	CF <sub>3</sub> NH NH  NH NH	N	
AstraZeneca \$3,394 Million RESPIRATORY DISORDERS  41 Aranesp	\$3,134 Million INFECTIOUS DISEASES  42 Gardasil/Gardasil 9	\$3,108 Million DIABETES  43 Lovenox	\$3,058 Million NEUROSCIENCE AND MENTAL HEALTH  Tysabri	\$2,842 Million DIABETES  45 Orencia	NOVARTIS \$2,776 Million NEUROSCIENCE AND MENTAL HEALTH  46 Xarelto	\$2,745 Million DIABETES  47 Eliquis	\$2,704 Million DIABETES  48 Lipitor	\$2,630 Million NEUROSCIENCE AND MENTAL HEALTH  49 Epogen	\$2,590 Million BLOOD RELATED DISORDERS  50 Invega Sustenna/Xeplion	\$2526 Million CARDIOVASCULAR  51 Stribild	AstraZeneca \$2,496 Million GASTROINTESTINAL DISORDERS  52 Prezista	\$2,493 Million ONCOLOGY  53 Remicade	\$2,477 Million ANTICOAGULANTS  54 Prograf	\$2,474 Million IMMUNOLOGY  55 Total Viagra	\$2,311 Million SEXUAL HEALTH  56 Human Insulins	\$2,231 Million ONCOLOGY  57 NovoMix/NovoLog Mix	\$2151 Million DIABETES  58 Viekira Pak	\$2122 Million CARDIOVASCULAR  59 Tasigna	\$2,060 Million OPTHAMOLOGY  60 Sandostatin
( Darbepoetin Alfa )	( Vaccine )	(Enoxaparin Sodium)	( Natalizumab )	( Abatacept )	( Rivaroxaban )	(Apixaban)	( Atorvastatin Calcium ) OOH HOO	(Epoetin Alfa)	( Paliperidone Palmitate )	(Cobicistat, Elvitegravir, Emtrícitabine & Tenofovir Disoproxil Fumarate)	(Darunavir)	(Infliximab)	( Tacrolimus )	( Sildenafil Citrate )	( Insulin )	(Insulin)	( Ombitasvir/Paritaprevir/Ritonavir )	( Nilotinib )	(Octreotide)
		HO S OH OH OH OH			O NH	N-N NH <sub>2</sub>	N NH	HO HO OH OH	N N O F	HO N OHO	HON NH2		O O O O O O O O O O O O O O O O O O O	O O N N N N N N N N N N N N N N N N N N	OH OH OH OH	OH OH OH OH	HN N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N	HN O NH OH  H2N H OH  H0 OH
\$1951 Million BLOOD RELATED DISORDERS	MERCK \$1,908 Million ONCOLOGY	\$1,891 Million ANTICOAGULANTS	Biogen. \$1,886 Million NEUROSCIENCE AND MENTAL HEALTH	Bristol-Myers Squibb \$1,885 Million IMMUNOLOGY	\$1,868 Million ANTICOAGULANTS	Bristol-Myers Squibb \$1,860 Million ANTICOAGULANTS	\$1,860 Million CARDIOVASCULAR	\$1,856 Million BLOOD RELATED DISORDERS	Janssen   PHABLIACEUTICAL COMPANIES of Schools Schools   \$1,830 Million NEUROSCIENCE AND MENTAL HEALTH	\$1,825 Million INFECTIOUS DISEASES	\$1,810 Million INFECTIOUS DISEASES	MERCK \$1,794 Million IMMUNOLOGY	**astellas \$1,713 Million IMMUNOLOGY	\$1,708 Million SEXUAL HEALTH	\$1,685 Million DIABETES	\$1,672 Million DIABETES	\$1,639 Million INFECTIOUS DISEASES	NOVARTIS \$1,632 Million ONCOLOGY	NOVARTIS \$1,630 Million ONCOLOGY
61 Sprycel (Dasatinib)	62 Afinitor/Votubia (Everolimus)	63 NovoSeven RT (Recombinant Human Coagulation Factor VIIa)	64 Lucentis (Ranibizumab)	65 Isentress (Raltegravir)	66 ProQuad/MMR II/Varivax ( Vaccine )	67 Polio/Pertussis/Hib ( Vaccine )	68 Perjeta ( Pertuzumab )	69 Actemra/RoActemra ( Tocilizumab )	70 Complera/Eviplera  (Rilpivirine, Emtricitabine, and Tenofovir Disoproxil Fumarate	71 MabThera/Rituxan (Rituximab)	72 Sensipar/Mimpara ( Cinacalcet )	73 Xgeva (Denosumab)	74 Eylea (Aflibercept )	75 Forteo (Teriparatide)  Ser Val Ser Glu lle Gin Leu  Met Leu His Lys Gly Leu Asn His	76 Velcade (Bortezomib)	77 Simponi/Simponi Aria ( Golimumab )	78 Prolia (Denosumab)	79 Baraclude (Entecavir)	80 Invokana/Invokamet  ( Canagliflozin )
HN O N OH	HO O O O O			HN O O					HN N N N N N N N N N N N N N N N N N N		CF <sub>3</sub>	9 8		Ser Met Giu Arg Val Giu Trp Leu Val Asp Gin Leu Lys Lys Arg	NH OHO BOH		9 8	HO NH NH2	HO, OH OH
Bristol-Myers Squibb \$1,620 Million ONCOLOGY	NOVARTIS \$1,607 Million ONCOLOGY	\$1,597 Million BLOOD RELATED DISORDERS	Roche \$1,535 Million OPTHAMOLOGY	MERCK \$1,511 Million INFECTIOUS DISEASES	MERCK \$1,505 Million VACCINE	SANOFI → \$1,483 Million VACCINE	Roche \$1,459 Million ONCOLOGY	Roche \$1,446 Million IMMUNOLOGY	\$1,427 Million INFECTIOUS DISEASES	Roche \$1,419 Million ONCOLOGY	AMGEN \$1,415 Million HORMONAL DISORDERS	AMGEN \$1,405 Million ONCOLOGY	\$1,351 Million DIABETES	S1,348 Million BONE HEALTH	Janssen   PRARMACEUTICAL COMPANIES or Confederate Companies or Concession of Concessio	Janssen PHARMACEUTICAL COMPANIES  \$1,328 Million IMMUNOLOGY	AMGEN \$1,312 Million BONE HEALTH	Bristol-Myers Squibb \$1,312 Million INFECTIOUS DISEASES	Janssen PRANMACEUTICA. COMPANIES \$1,308 Million TYPE 2 DIABETES
81 <b>Humulin</b> (Insulin Isophane)	82 Xolair (Omalizumab)	83 Diovan  (Hydrochlorothiazide and Valsartan)  OHHN-N N N N	84 Kogenate ( Antihemophilic Factor (Recombinant) )	85 Sustiva ( Efavirenz )	86 <b>Vytorin</b> (Ezetimibe and Simvastatin)	87 Xtandi ( Enzalutamide )	88 Tarceva ( Erlotinib )	89 Vesicare ( Solifenacin Succinate )	90 Norditropin (Somatropin)	91 Galvus ( Vildagliptin )	92 Reyataz ( Atazanavir Sulphate )	93 Cubicin ( Daptomycin )	94 Yervoy ( Ipilimumab )	95 Sutent ( Sunitinib Malate )	96 Viread (Tenofovir Disoproxil Fumarate)	97 Procrit/Eprex (Epoetin Alfa)	98 Mirena Product Family ( Levonorgestrel )	99 Neupogen (Filgrastim)	100 Exforge ( Amlodipine and Valsartan. )
		CI		CI CF <sub>3</sub>	HO HO O HO O HO O O O O O O O O O O O O	F N S CF <sub>3</sub>	O O N N N HN			HO N N	O NH OH NH NH			F N N H	N O PO	HO HO OH OH	O H H H H		O OH HN-N
<b>Lilly</b> \$1,307 Million DIABETES	Roche \$1,290 Million RESPIRATORY DISORDERS	NOVARTIS  \$1,284 Million  ANTIHYPERTENSIVES	\$1,271 Million RARE DISEASE	Bristol-Myers Squibb \$1,252 Million INFECTIOUS DISEASES	MERCK \$1,251 Million CARDIOVASCULAR	**astellas \$1,207 Million ONCOLOGY	Roche \$1,193 Million ONCOLOGY	astellas \$1,190 Million OVERACTIVE BLADDER	\$1,173 Million HORMONAL DISORDERS	NOVARTIS \$1,140 Million DIABETES	Bristol-Myers Squibb \$1,139 Million INFECTIOUS DISEASES	MERCK \$1,127 Million ANTI-BACTERIAL	Bristol-Myers Squibb \$1,126 Million ONCOLOGY	<b>Pfizer</b> \$1,120 Million ONCOLOGY	\$1,108 Million INFECTIOUS DISEASES	Janssen   PHARMACEUTICAL COMPANIES  \$1,068 Million  BLOOD RELATED DISORDERS	\$1,065 Million SEXUAL HEALTH	AMGEN \$1,049 Million BLOOD RELATED DISORDERS	NOVARTIS \$1,047 Million
101 Infanrix, Pediarix ( Vaccine )	102 Triumeq  (Abacavir, Dolutegravir and Lamivudine)	103 Renagel/Renvela (Sevelamer Hydrochloride and Sevelamer Carbonate)	104 Cymbalta (Duloxetine)	105 Seroquel XR ( Quetiapine Fumarate )	106 Pulmicort ( Budesonide )	107 Epzicom/Kivexa ( Abacavir and Lamivudine )	108 Norvasc ( Amlodipine )	109 Pomalyst/Imnovid ( Pomalidomide )	110 Nexavar (Sorafenib)	111 Risperdal Consta (Risperidone)	112 Abraxane ( Paclitaxel protein-bound )	113 Aubagio ( Teriflunomide )	114 Activase/TNKase (Tenecteplase)	115 Opdivo ( Nivolumab )	116 Zyprexa (Olanzapine)	117 Avodart ( Dutasteride )	118 Singulair ( Montelukast Sodium )	119 Exjade ( Deferasirox )	120Betaferon/Betaseron (Interferon Beta-1b)
	OH NH2	H <sub>2</sub> N a HN OH HN m	N N	N—OH N S	HO HO H	H <sub>2</sub> N N N NH <sub>2</sub>	H <sub>2</sub> N O	$NH_2$ $O$ $N$	NH NH CI FFF		NH HO O O OH OH OO O	F <sub>3</sub> C OH			N S	O N H CF <sub>3</sub> O N H F <sub>3</sub> C	НО	N HO OH	
gsk GlaxoSmithKline \$1,041 Million VACCINE	gsk GlaxoSmithKline \$1,037 Million INFECTIOUS DISEASES	SANOFI S \$1,029 Million UROLOGY	<b>Lilly</b> \$1,028 Million NEUROSCIENCE AND MENTAL HEALTH	AstraZeneca \$1,025 Million NEUROSCIENCE AND MENTAL HEALTH	AstraZeneca \$1,014 Million RESPIRATORY DISORDERS	S—OH  SSK GlaxoSmithKline  \$991 Million  INFECTIOUS DISEASES	*## \$991 Million  ANTIHYPERTENSIVES	\$983 Million ONCOLOGY	\$981 Million ONCOLOGY	Janssen Jansse	\$968 Million ONCOLOGY	SANOFI • \$958 Million  NEUROSCIENCE AND MENTAL HEALTH	Roche \$944 Million CARDIOVASCULAR	Bristol-Myers Squibb  \$942 Million ONCOLOGY	<b>Lilly</b> \$940 Million NEUROSCIENCE AND MENTAL HEALTH	gsk GlaxoSmithKline \$933 Million UROLOGY	**MERCK  \$931 Million  RESPIRATORY DISORDERS	NOVARTIS  \$917 Million  ONCOLOGY	Bayer \$906 Million NEUROSCIENCE AND MENTAL HEALTH
121 Flixotide/Flovent (Fluticasone Propionate)	122 Zyvox ( Linezolid )	123 Ventolin ( Albuterol )	124 Nasonex ( Mometasone Furoate )	125 Aprovel/CoAprovel Irbesartan / Irbesartan+Hydrochlorothiazide	126 <b>Tivicay</b> ( Dolutegravir )	127 Cerezyme ( Imiglucerase )	128 Celebrex ( Celecoxib )	129 Lupron ( Leuprolide acetate )	130 Concerta ( Methylphenidate )	131 Zoladex (Goserelin Acetate)	132 CellCept ( Mycophenolate Mofetil )	133 Onglyza/Kombiglyze XR (Saxagliptin/Saxagliptin+Metoprolol Hydrochloride)	134 Strattera ( Atomoxetine )	135 YAZ/Yasim ( Drospirenone and Ethinyl Estradiol	136 Kadcyla ( Trastuzumab Emtansine )	137 Synthroid ( Levothyroxine Sodium )	138 Xolair (Omalizumab)	139 Imbruvica (Ibrutinib)	140 Lamictal (Lamotrigine)
HO H H H	N N NH	N OH OH	HO H H		OH NH F		H <sub>2</sub> N S F F		O H N	HN NH NH2	OH O	HO H <sub>2</sub> N "H	O ZI	H H H H		HO OH NH <sub>2</sub>		N N N N N N N N N N N N N N N N N N N	N=N $N=N$
<b>QSK</b> GlaxoSmithKline \$885 Million RESPIRATORY DISORDERS	\$883 Million	\$880 Million	\$858 Million	SANOFI SA	gsk GlaxoSmithKline \$835 Million	\$833 Million	<b>Pfizer</b> \$830 Million BONE HEALTH	abbvie \$826 Million ONCOLOGY	Janssen   PHARMACEUTICAL COMPANIES or Schwert-Schwert \$821 Million NEUROSCIENCE AND MENTAL HEALTH	AstraZeneca \$816 Million	Roche \$793 Million	AstraZeneca \$786 Million	<b>Lilly</b> \$784 Million NEUROSCIENCE AND MENTAL HEALTH	Bayer \$777 Million SEXUAL HEALTH	Roche \$777 Million	abbvie \$755 Million HORMONAL DISORDERS	NOVARTIS  \$755 Million  RESPIRATORY DISORDERS	abbvie  \$754 Million  CHRONIC LYMPHOCYTIC LEUKEM	\$754 Million  NEUROSCIENCE AND MENTAL HEALTH
141 BeneFIX (Coagulation Factor IX)	142 Augmentin (Amoxicillin and Clavulanate Potassium)	, (	144 Abilify ( Aripiprazole )	145 Treanda (Bendamustine)	146 Synagis ( Palivizumab )	147 NuvaRing ( Ethinyl Estradiol And Etonogestrel )	148Exelon/Exelon Patch ( Rivastigmine )	149 Ibrance ( Palbociclib )	150 Pristiq ( Desvenlafaxine )	151Myozyme/Lumizyme ( Alglucosidase alfa )	152 Tamiflu ( Oseltamivir Phosphate )	153 Seloken /Toprol-XL ( Metoprolol Hydrochloride )	154 Faslodex ( Fulvestrant )	155 Kaletra (Lopinavir/Ritonavir)	156 Letairis ( Ambrisentan )	157 Adalat (Nifedipine)	158 Androgel (Testosterone)	159 Simponi ( Golimumab )	160 Imbruvica ( Ibrutinib )
	OH H H S OH		N CI CI N O	CI N O OH		HO H H H OH	N O N	O N N N N N N N N N N N N N N N N N N N	OH OH OH		NH NH <sub>2</sub>	O NH OH	HO H H H	HN O NH ONH	N O OH	NO <sub>2</sub>	OH H H		N N N N N N N N N N N N N N N N N N N
<b>Pfizer</b> \$752 Million RARE DISEASE	gsk GlaxoSmithKline \$750 Million ANTI-BACTERIAL	\$749 Million INFECTIOUS DISEASES	Bristol-Myers Squibb  \$746 Million  NEUROSCIENCE AND MENTAL HEALTH	\$741 Million ONCOLOGY	abbvie  \$740 Million  RESPIRATORY DISORDERS	**MERCK  \$732 Million  SEXUAL HEALTH	NOVARTIS  \$728 Million  NEUROSCIENCE AND MENTAL HEALTH	<b>Pfizer</b> \$723 Million ONCOLOGY	<b>Prizer</b> \$715 Million NEUROSCIENCE AND MENTAL HEALTH	\$ANOFI \$715 Million RARE DISEASE	Roche \$712 Million INFECTIOUS DISEASES	AstraZeneca \$710 Million ANTIHYPERTENSIVES	AstraZeneca \$704 Million ONCOLOGY	abbvie \$700 Million INFECTIOUS DISEASES	GILEAD  \$700 Million  ANTIHYPERTENSIVES	\$696 Million ANTIHYPERTENSIVES	abbvie \$694 Million HORMONAL DISORDERS	*## MERCK \$690 Million IMMUNOLOGY	Janssen PRANMACEUTICAL COMPANIES  \$689 Million  ONCOLOGY
161 Vfend ( Voriconazole )	162Meningitis/Pneumonia ( Vaccine )	163 Chantix/Champix (Varenicline)	164 Cozaar/Hyzaar (Losartan and Hydrochlorothiazide	165 Synagis ( Palivizumab )	166 Pulmozyme ( Dornase Alfa )	167 Fabrazyme ( Agalsidase beta )	168 Creon ( Pancrelipase )	169 Kalydeco (Ivacaftor)	170 Olysio/Sovriad (Simeprevir)	171 Brilinta/Brilique (Ticagrelor)	172 Genotropin (Somatropin)	173 RotaTeq (Vaccine)	174 Rotarix (Vaccine)	175 Vidaza ( Azacitidine )	176 Ranexa (Ranolazine)	177 Implanin/Nexplanon (Etonogestrel)	178 Bydureon (Exenatide)	179 Aspirin Cardio ( Acetylsalicylic Acid )	180 Glucobay (Acarbose)
F OH N F N		HN	CI OH CI OH NH					OH OH OH	N O O O O O O O O O O O O O O O O O O O	HN N F F HO O OH				NH <sub>2</sub> N N N HO OH	N H O	OH H H	His Gly Glu Gly Thr Phe Thr Ser  Asp  Glu Glu Glu Met Gin Lys Ser Leu  Ala  Val Arg Leu Phe IIe Glu Trp Leu  Lys  Ala Gly Ser Ser Pro Gly Gly Asn	O O O H	HO HO OH HO OH HO HO HO HO HO HO HO HO H
<b>Pfizer</b> \$682 Million ANTI-FUNGAL	SANOFI S \$675 Million VACCINE	*\$671 Million  NEUROSCIENCE AND MENTAL HEALTH	*## MERCK \$667 Million ANTIHYPERTENSIVES	AstraZeneca \$662 Million RESPIRATORY DISORDERS	Roche \$659 Million RARE DISEASE	SANOFI >> \$651 Million RARE DISEASE	abbvie \$632 Million RARE DISEASE	VERTEX \$632 Million RESPIRATORY DISORDERS	Janssen Jansse	AstraZeneca \$619 Million CARDIOVASCULAR	*## \$617 Million RARE DISEASE	**MERCK \$610 Million VACCINE	GlaxoSmithKline \$592 Million VACCINE	\$591 Million ONCOLOGY	GILEAD  \$588 Million  CARDIOVASCULAR	**S88 Million SEXUAL HEALTH	AstraZeneca \$580 Million DIABETES	\$576 Million CARDIOVASCULAR	\$575 Million DIABETES
181 Invega ( Paliperidone )	182 Cancidas (Caspofungin)	183 Neoral/Sandimmun ( Cyclosporine )	184 Invanz (Ertapenem)	185 Esbriet ( Pirfenidone )	186 Keytruda (Pembrolizumab)	187 Votrient (Pazopanib)	188 Voltaren ( Diclofenac )	189 Vectibix ( Panitumumab )	190 ProAir ( Albuterol Sulfate )	191 Iressa ( Gefitinib )	192 Pegasys ( Peginterferon Alfa-2a )	193 Pneumovax 23 ( Vaccine )	194 Synflorix (Vaccine)	195 Dulera (Formoterol and Mometasone)	196 Emend ( Aprepitant )	197 Refacto AF/Xyntha (Antihemophilic Factor (Recombinant))	198 Nplate ( Romiplostim )	199 Effient ( Prasugrel )	200 Xeljanz (Tofacitinib citrate)
HO N O N O N O	HO HN OH HN OH HO	O N N N N N N N N N N N N N N N N N N N	HO H H	O N		$\begin{array}{c c} N & & \\ N & &$	CI NH CI OH		HO HO OH H	ON ON N		PNEUMOVAX® 23 Insurmococcal vaccins polyvalent, MSDI .25 mcg/0.5 mL Tor Subcutaneous or I.M. Use Only 1 Dose Vial 0.5 mL	Symbolic Management of the state of the stat	HO O CI OH HO I I I I I I I I I I I I I I I I	HN NH O CF3			O S O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N
Janssen Jansse	MERCK \$573 Million ANTI-FUNGAL	NOVARTIS  \$570 Million  IMMUNOLOGY	MERCK  \$569 Million ANTI-BACTERIAL	Roche \$569 Million IDIOPATHIC PULMONARY FIBROSIS	MERCK  \$566 Million ONCOLOGY	NOVARTIS  \$565 Million  ONCOLOGY	NOVARTIS  \$558 Million  OTHERS	AMGEN \$549 Million ONCOLOGY	\$549 Million RESPIRATORY DISORDERS	AstraZeneca \$543 Million ONCOLOGY	Roche \$543 Million INFECTIOUS DISEASES	MERCK  \$542 Million  VACCINE	gsk GlaxoSmithKline \$541 Million VACCINE	MERCK \$536 Million RESPIRATORY DISORDERS	*## MERCK  \$535 Million  OTHERS	<b>Pfizer</b> \$533 Million RARE DISEASE	AMCEN \$525 Million IMMUNOLOGY	<b>Liley</b> \$523 Million CARDIOVASCULAR	*\$523 Million IMMUNOLOGY